Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ740MR)

This product GTTS-WQ740MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ740MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2100MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ11546MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ10655MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ1760MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ814MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11583MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ11075MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ8457MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW